Cefditoren Pivoxil, ME-1207, Meiact

Cefditoren Pivoxil, ME-1207, Meiact Brand names, Cefditoren Pivoxil, ME-1207, Meiact Analogs

Cefditoren Pivoxil, ME-1207, Meiact Brand Names Mixture

No information avaliable

Cefditoren Pivoxil, ME-1207, Meiact Chemical_Formula

C₂₅H₂₈N₆O₇S₃

Cefditoren Pivoxil, ME-1207, Meiact RX_link

http://www.rxlist.com/cgi/generic3/spectracef.htm

Cefditoren Pivoxil, ME-1207, Meiact fda sheet

Cefditoren_Pivoxil,_ME-1207,_Meiact FDA

Cefditoren Pivoxil, ME-1207, Meiact msds (material safety sheet)

Cefditoren Pivoxil, ME-1207, Meiact Synthesis Reference

No information avaliable

Cefditoren Pivoxil, ME-1207, Meiact Molecular Weight

620.724 g/mol

Cefditoren Pivoxil, ME-1207, Meiact Melting Point

127 - 129 ^oC

Cefditoren Pivoxil, ME-1207, Meiact H₂O Solubility

Soluble at levels equal to < 0.1 mg/mL.

Cefditoren Pivoxil, ME-1207, Meiact State

Solid

Cefditoren Pivoxil, ME-1207, Meiact LogP

2.721

Cefditoren Pivoxil, ME-1207, Meiact Dosage Forms

Tablets (200mg) for oral administration.

Cefditoren Pivoxil, ME-1207, Meiact Indication

For the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.

Cefditoren Pivoxil, ME-1207, Meiact Pharmacology

Cefditoren pivoxil is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active cefditoren. Cefditoren is a cephalosporin with antibacterial activity against gram-positive and gram-negative pathogens. Cefditoren is effective against Staphylococcus aureus (methicillin-susceptible strains, including b-lactamase-producing strains), penicillin-susceptible strains of Staphylococcus aureus and Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae (including b-lactamase-producing strains), Haemophilus parainfluenzae (including b-lactamase-producing strains), Moraxella catarrhalis (including b-lactamase-producing strains), Streptococcus agalactiae, Streptococcus Groups C and G, and Streptococcus, viridans group (penicillin-susceptible and -intermediate strains).

Cefditoren Pivoxil, ME-1207, Meiact Absorption

Following oral administration, cefditoren pivoxil is absorbed from the gastrointestinal tract and hydrolyzed to cefditoren by esterases. Under fasting conditions, the estimated absolute bioavailability of cefditoren pivoxil is approximately 14%. The absolute bioavailability of cefditoren pivoxil administered with a low fat meal (693 cal, 14 g fat, 122 g carb, 23 g protein) is 16.1 ± 3.0%.

Cefditoren Pivoxil, ME-1207, Meiact side effects and Toxicity

Information on cefditoren pivoxil overdosage in humans is not available. However, with other b-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. In acute animal toxicity studies, cefditoren pivoxil when tested at the limit oral doses of 5100 mg/kg in rats and up to 2000 mg/kg in dogs did not exhibit any health effects of concern.

Cefditoren Pivoxil, ME-1207, Meiact Patient Information